Study #2022-0186
An Open-label, Phase 1b Study of R289, an IRAK1/4 Inhibitor, in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS) Who are Refractory/Resistant to Prior Therapies
MD Anderson Study Status
Enrolling
Treatment Agent
R906289 Monosodium (R289 Na)
Description
Phase 1b Study of R289 in Participants with Lower-risk Myelodysplastic Syndromes (LR MDS)
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Low Risk Myelodysplastic Syndromes
Study phase:
Physician name:
Guillermo Garcia-Manero
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.